Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge.

This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation, and what the future might hold for his “pipeline in a product”.

01:26   Introducing Niels Riedemann

04:28   InflaRx and its mission

06:37   The competitive landscape in anti-inflammatory therapeutics

07:21   The market for anti-inflammatories

08:40   The challenge of taking a drug from R&D to commercialization

11:06   The science behind the C5a and C5aR approach

14:37   Why is InflaRx the first to focus on these selective inhibitors?

19:18   The importance of the MAC formation

21:05   InflaRx and its disease targets

25:46   Applications beyond anti-inflammatories

27:50   Lessons learned from the clinic

29:54   Growth forecasts for InflaRx

31:48   Different approaches to addressing inflammation

33:51   The role of academia in breakthrough therapies

36:11   Beyond Europe and North America, addressing the global demand for therapeutics

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• Why is the immunology and inflammation market suddenly attracting a wave of investment?
• Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to Treat
• JAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?